Emergent’s approach is to achieve balance in the products that we develop through a pipeline comprising innovative vaccines and therapeutics that target diseases worldwide.
Program
WEVEE VLP
(Western, Eastern and Venezuelan equine encephalitic VLP)
Pre Clinical
Phase 1
Phase 2
Phase 3
Phase 4
Pan-Ebola mAb
(Ebola/Sudan monoclonal)
Pre Clinical
Phase 1
Phase 2
Phase 3
Phase 4